Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging
Moderna (MRNA) and Merck (MRK) stocks surged after announcing positive late-stage melanoma vaccine trial results. The trial combined Moderna's mRNA technology with Merck's Keytruda drug. Analysts from Bank of America and Morgan Stanley raised price targets for Moderna, citing the vaccine's potential. Merck reported strong sales growth for Keytruda and other drugs, but posted a net loss in Q2. Hedge fund activity and short interest were noted for both companies.
How this was made
The 30-second read
Why it matters
The data represents a material catalyst for both companies, potentially reshaping valuation models.
Market read
Trial results could trigger buying pressure in biotech and pharma stocks.
What to watch
Regulatory approval timeline and competitive landscape for melanoma therapies.
Background
The article reports first‑time disclosure of Moderna's melanoma vaccine trial results in partnership with Merck.
Ticker impact
Moderna announced late‑stage melanoma vaccine trial results showing a combined response with Merck's Keytruda, driving a 176% stock surge.
upward pressure on MRNA over the next weeks
Phase‑2 data for a new oncology indication is material and rare for a biotech, likely to attract investors.
Merck's Keytruda partnership in the melanoma trial contributed to a 12.6% stock rise after the announcement.
moderate upside for MRK in the near term
The trial boost is secondary to Moderna's data, but reinforces Merck's oncology pipeline.
Market effects
Positive oncology trial data may lift biotech and pharma peers.
U.S. biotech sector could see increased investor inflows.
Global cancer‑drug market outlook improves.
Counterpoint
Skeptics may point to Moderna's cash burn and prior vaccine setbacks.
Key entities
- companyModerna Inc.
Biotech firm developing mRNA‑based vaccines.
- companyMerck & Co., Inc.
Pharmaceutical giant with Keytruda oncology portfolio.
